Related Experiment Videos
Left ventricular dysfunction and cytoprotection
1Cardiology Department, Coimbra University Hospital Medical School, Coimbra University, Portugal. lgoncalv@ci.uc.pt
Insights
Heart failure worsens due to myocyte apoptosis, a process triggered by various factors. Therapies targeting these triggers and preserving mitochondrial function may protect heart cells and reduce heart failure progression.
Area of Science:
- Cardiovascular Research
- Cellular Biology
- Pathophysiology
Background:
- Heart failure is a growing concern due to population aging.
- Myocyte apoptosis significantly contributes to heart failure progression.
- Understanding apoptosis triggers is crucial for developing effective treatments.
Purpose of the Study:
- To explore the mechanisms of myocyte apoptosis in heart failure.
- To identify potential therapeutic targets for cytoprotection.
- To highlight the role of mitochondria in myocyte viability.
Main Methods:
- Review of existing knowledge on heart failure pathophysiology.
- Analysis of apoptosis-inducing factors (e.g., adrenergic stimulation, angiotensin II).
- Examination of the role of mitochondrial function in myocyte survival.
Main Results:
- Myocyte apoptosis leads to a decrease in cardiac myocytes, worsening heart failure.
- Apoptosis can be initiated by adrenergic stimulation, angiotensin II, and metabolic changes.
- Mitochondrial dysfunction severely compromises myocyte viability.
Conclusions:
- Inhibiting apoptosis triggers with drugs like beta-blockers or ACE inhibitors may offer cytoprotection.
- Therapies that prevent mitochondrial dysfunction are vital for cytoprotection in heart failure.
- Targeting apoptosis and mitochondrial health presents a promising strategy for heart failure management.
Abstract:
With the projections of increasing aging of the population, heart failure is expected to become a major health problem for most Western societies. Therefore, the study of the pathophysiological mechanisms involved in heart failure should be one of the main priorities of cardiovascular research. A substantial amount of knowledge has been gathered in the recent years on the mechanisms involved in the development of heart failure. One such mechanism is the development of myocyte's apoptosis. This apoptotic mechanism is responsible for a substantial decrease in the number of cardiac myocytes, and therefore for the worsening of heart failure. This apoptotic mechanism can be triggered by a number of mechanisms such as the adrenergic stimulation, the angiotensin II production, changes in calcium homeostasis, and changes in cellular metabolism. At least in theory, the development of therapies (such as beta blockers, ACE inhibitors, calcium channel blockers and trimetazidine) that can inhibit these mechanisms can have a cytoprotective role and therefore reduce the development of heart failure. Because of its main role in the production of energy for the cell, the mitochondrion is one of the mainframes of cell viability. If the mitochondrial function is decreased the myocyte will be in jeopardy. Therefore, drugs that can prevent mitochondrial dysfunction will obviously have a cytoprotective role in heart failure.